Trevi Therapeutics Inc. announced the publication of key results from its Phase 2b CORAL trial evaluating oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). The data, published in the Journal of the American Medical Association (JAMA), demonstrated a statistically significant reduction in 24-hour objective cough frequency across all dose groups at Week 6, with significant improvement observed as early as Week 2. Over 60% of patients treated with nalbuphine ER achieved at least a 50% reduction in 24-hour cough frequency at Week 6 compared to baseline. Patient-reported outcomes were consistent with objective cough monitoring results. The results have already been presented through the JAMA publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY68402) on January 22, 2026, and is solely responsible for the information contained therein.